On July 28, 2025, Adaptimmune announced entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Read MoreOur Pipeline
Adaptimmune is developing an industry-leading T cell therapy pipeline in solid tumors and has a deep pipeline of identified and proprietary targets for further product development.
| Program [Target] | Trial Name(s) / Indications / Design | Ind-Enabling | Phase 1 | Phase 2/3 | Registration | |
|---|---|---|---|---|---|---|
| ADP-600 [PRAME] | Indications that express PRAME including synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian and head & neck cancers. Clinical Indications TBD | |||||
| ADP-520 [CD70] | Indications that express CD70 including hematological, malignancies, acute myeloid leukemia (AML), lymphoma and renal cell carcinoma (RCC). Clinical Indications TBD | |||||